![iTeos Therapeutics, Inc. logo](/logos/ITOS.webp)
iTeos Therapeutics, Inc.
NASDAQ:ITOS
Overview | Financials
Company Name | iTeos Therapeutics, Inc. |
Symbol | ITOS |
Currency | USD |
Price | 14.8 |
Market Cap | 540,522,640 |
Dividend Yield | 0% |
52-week-range | 8.2 - 18.75 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Michel Detheux Ph.D. |
Website | https://www.iteostherapeutics.com |
An error occurred while fetching data.
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD